• A+ Standard
  • A+ Larger
  • A+ Extra Large

  • Standard Contrast
  • Low Contrast
  • High Contrast

Discovery of PRT3789, a First-in-Class Potent and Selective SMARCA2 Degrader in Clinical Trials for the Treatment of Patients With SMARCA4 Mutated Cancers

Koichi Ito, Michael Hulse, Anjana Agarwal, Jack Carter, Monisha Sivakumar, Komali Vykuntam, Min Wang, Miles Cowart, Joy Cote, William Gowen-MacDonald, Brian Vidal Torres, Justin Kurian, Neha Bhagwat, Norman Fultang, Alexander Grego, Andrew Moore, Ashley Schwab, Jessica Burtell, Olusola Peace Osinubi, Jacob Spruance, Liang Lu, Philip Pitis, Corey Basch, Klare Bersch, Chaofeng Dai, Raul Leal, Artem Shvartsbart, Ganfeng Cao, Bo Shen, Patrick Wen, Joseph Rager, Ross Kuskovsky, Bob Landman, Tom Emm, Stefan Ruepp, Chunhua Qin, Gina Paris, Jennifer Xavier, Rachel Chiaverelli, Sang Hyun Lee, Sandy Geeganage, Hong Lin, Diane Heiser, Bruce Ruggeri, Naveen Babbar, Andrew Combs, Peggy Scherle

Poster presented at the

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023, October 11-15, 2023, Boston, MA, USA

This is an electronic reproduction of a poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023, October 11-15, 2023, Boston, MA, USA. All copyrights remain those of the copyright holder. This page will not be available after November 14, 2023.